Everest Medicines Limited (1952.HK)

HKD 46.4

(-6.64%)

Total Debt Summary of Everest Medicines Limited

Everest Medicines Limited's latest annual total debt in 2023 was 510.62 Million CNY , up 1.37% from previous year.
Everest Medicines Limited's latest quarterly total debt in 2024 Q1 was - CNY , down -100.0% from previous quarter.
Everest Medicines Limited reported annual total debt of 503.71 Million CNY in 2022, up 3.85% from previous year.
Everest Medicines Limited reported annual total debt of 485.03 Million CNY in 2021, up 8.43% from previous year.
Everest Medicines Limited reported quarterly total debt of 520.58 Million CNY for 2023 Q3, up 80.46% from previous quarter.
Everest Medicines Limited reported quarterly total debt of 510.62 Million CNY for 2023 FY, up 1.37% from previous quarter.

Annual Total Debt Chart of Everest Medicines Limited (2023 - 2018)

Historical Annual Total Debt of Everest Medicines Limited (2023 - 2018)

Year	Total Debt	Total Debt Growth
2023	510.62 Million CNY	1.37%
2022	503.71 Million CNY	3.85%
2021	485.03 Million CNY	8.43%
2020	447.33 Million CNY	997.5%
2019	40.75 Million CNY	143.51%
2018	16.73 Million CNY	0.0%

Year	Total Debt	Total Debt Growth
2024 Q1	- CNY	-100.0%
2023 Q3	520.58 Million CNY	80.46%
2023 FY	510.62 Million CNY	1.37%
2023 Q4	510.62 Million CNY	-1.91%
2023 Q2	288.48 Million CNY	-7.04%
2023 Q1	310.31 Million CNY	-38.39%
2022 Q4	503.71 Million CNY	-2.06%
2022 Q3	514.31 Million CNY	1.21%
2022 Q2	508.14 Million CNY	-0.03%
2022 Q1	508.28 Million CNY	4.79%
2022 FY	503.71 Million CNY	3.85%
2021 Q3	483.56 Million CNY	11.39%
2021 Q2	434.1 Million CNY	-0.19%
2021 Q1	434.94 Million CNY	-3.17%
2021 FY	485.03 Million CNY	8.43%
2021 Q4	485.03 Million CNY	0.3%
2020 Q4	449.19 Million CNY	0.0%
2020 Q1	49.23 Million CNY	0.0%
2020 Q3	449.19 Million CNY	0.0%
2020 Q2	- CNY	-100.0%
2020 FY	447.33 Million CNY	997.5%
2019 FY	40.75 Million CNY	143.51%
2019 Q1	- CNY	0.0%
2018 FY	16.73 Million CNY	0.0%

Peer Total Debt Comparison of Everest Medicines Limited

Name	Total Debt	Total Debt Difference
Uni-Bio Science Group Limited	52.86 Million HKD	-865.869%
CK Life Sciences Int'l., (Holdings) Inc.	5.93 Billion HKD	91.391%